Biotechnology Assets SA BST
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- €0.21
- Day Range
- €0.20–0.20
- 52-Week Range
- €0.18–0.39
- Bid/Ask
- €0.20 / €0.20
- Shares Outstanding
- 76.09M
- Market Cap
- €14.99M
- Volume/Avg
- 96,345 / 126,400
Key Statistics
- Price/Earnings (Normalized)
- 0.83
- Price/Sales
- 4.34
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Biotechnology Assets SA is a clinical-stage biopharmaceutical company developing and producing biological products for the pharmaceutical and veterinarian sectors. It specializes in the prevention and treatment of niche diseases, such as orphan disease, antigens for new-generation vaccines, feed additives, and probiotics. Adl Bionatur offers a portfolio of non-therapeutic and therapeutic products to tier 1 and tier 2 animal health companies. The company's pipeline products include BNT006, BNT007, BNT010, and others.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 27
- Website
- https://www.biatgroup.com
Valuation
|
Metric
|
BST
|
|---|---|
Price/Earnings (Normalized) | 0.83 |
Price/Book Value | 2.06 |
Price/Sales | 4.34 |
Price/Cash Flow | 19.38 |
Price/Earnings
BST
Financial Strength
|
Metric
|
BST
|
|---|---|
Quick Ratio | 1.39 |
Current Ratio | 1.40 |
Interest Coverage | −10.85 |
Quick Ratio
BST
Profitability
|
Metric
|
BST
|
|---|---|
Return on Assets (Normalized) | −9.87% |
Return on Equity (Normalized) | −20.60% |
Return on Invested Capital (Normalized) | −11.34% |
Return on Assets
BST
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|XxPS>NZ | LOCK|cFJ^Y | $123B | |||
| Moderna Inc
MRNA
| LOCK|b#!$><c | LOCK|W^ | $86B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|lpCZMP | LOCK|GT^$l | $78B | |||
| argenx SE ADR
ARGX
| LOCK|&?mbWf@ | LOCK|MJq | $50B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|&D&#Y& | LOCK|h$ | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|Dy@TlcW | LOCK|&Zbp@ | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|^^^&Bh? | LOCK|#pnv | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|CBcJ<YM | LOCK|pV | $22B | |||
| Incyte Corp
INCY
| LOCK|%#@>zl | LOCK|!r | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|Sn<rvY | LOCK|HwG | $14B |
United States